Basmisanil - Roche
Alternative Names: GABRA5 negative allosteric modulator (NAM) - Roche; NTX-1511; RG-1662; RO-5186582Latest Information Update: 14 Aug 2025
At a glance
- Originator Roche
- Developer Chugai Pharmaceutical; Newleos Therapeutics; Roche
- Class Antidementias; Oxazoles; Pyridines; Small molecules; Thiamorpholines
- Mechanism of Action GABA A alpha 5 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chromosome disorders
- Discontinued Down syndrome; Neurological disorders; Schizophrenia
Most Recent Events
- 06 Aug 2025 Phase-II clinical trials in Chromosome disorders (PO) prior to August 2025 (Newleos Therapeutics pipeline, August 2025)
- 13 Feb 2025 RO 7308480 licensed to Newleos Therapeutics
- 04 Mar 2024 Discontinued - Phase-II for Chromosome disorders (In adolescents, In children) in USA, Portugal, Poland (PO) (NCT05307679)